Elevance Health vs UnitedHealth ELV vs UNH
Elevance Health and UnitedHealth on one sheet: valuation multiples, growth, margins, debt, dividends and returns, each section labelled with the period it covers, from the companies' filings. Add or remove a stock above the sheet; the link holds the set.
What differs most
- Market value: UnitedHealth $368.64B, Elevance Health $93.54B.
- Price / sales: UnitedHealth 0.8×, Elevance Health 0.5×.
- One-year price return: Elevance Health +26.0%, UnitedHealth +13.3%.
- Operating margin: UnitedHealth 5.3%, Elevance Health 3.7%.
Price return
2025-10-26 → 2026-10-26
ELV+26.0%
UNH+13.3%
Profile
latestSector
Healthcare
Healthcare
Industry
Medical - Healthcare Plans
Medical - Healthcare Plans
Market value
$93.54B
$368.64B
Enterprise value
$113.95B
$417.13B
Employees
96,615
390,000
Revenue per employee (TTM)
$2.1M
$1.2M
Our models
nightlythe valuation on each stock's pagePrice vs model
24% undervalued vs model
31% overvalued vs model
Model range
$306–1481
$182–845
Models in the headline
1
1
FCF growth priced in, at a 10% return
20.9%
14.3%
Every model, its assumptions and its range: ELV valuation · UNH valuation. The growth priced in, at any return: ELV reverse DCF · UNH reverse DCF.
Trading
close 2026-10-26Last close
$431.32
$410.70
52-week high
$445.28
$436.35
52-week low
$280.74
$259.02
Price vs 52-week high
−3.1%
−5.9%
Price vs 52-week low
+53.6%
+58.6%
Average daily volume / shares
0.6%
0.6%
Beta
0.71
0.61
Returns
to 2026-10-261 month
+8.9%
+9.1%
3 months
+14.2%
−2.4%
6 months
+25.1%
+15.7%
Year to date
+23.0%
+24.4%
1 year
+26.0%
+13.3%
1 year, dividends added
+28.0%
+15.8%
2 years
+1.4%
−27.3%
Valuation
price × TTM to Sep 2026P/E (TTM)
18.4×
23.4×
P/E on consensus EPS (next FY)
15.5×
20.0×
Price / sales
0.5×
0.8×
EV / sales
0.6×
0.9×
EV / EBITDA
12.8×
14.9×
Price / book
2.1×
3.5×
Price / free cash flow (FY)
29.5×
22.9×
Free-cash-flow yield (FY)
3.4%
4.4%
Growth
TTM and FY2025Revenue growth (TTM)
—
—
Revenue growth, consensus next FY
−0.4%
+0.1%
Revenue, 3-year CAGR
8.3%
11.4%
Revenue, 5-year CAGR
10.3%
11.7%
EPS growth (TTM)
—
—
EPS growth, consensus next FY
+11.0%
+55.5%
EPS, 3-year CAGR
1.1%
−14.5%
Free cash flow, 3-year CAGR
−24.1%
−11.8%
Diluted shares, 3-year change
−8.6%
−4.2%
Profitability
TTM to Sep 2026Gross margin (FY)†
25.6%
18.5%
Operating margin
3.7%
5.3%
EBITDA margin
4.4%
6.2%
Net margin
2.5%
3.5%
Free-cash-flow margin (FY)
1.6%
3.6%
Return on equity
11.5%
15.3%
Return on assets
4.0%
5.1%
Asset turnover
1.58
1.44
† Gross margin (FY): As filed. Companies draw the cost-of-revenue line in different places, so gross margins of two companies in one industry can differ for that reason alone; operating margin does not depend on where the line is drawn.
Balance sheet
MRQ Sep 2026Cash
$10.35B
$25.84B
Total debt
$30.76B
$74.33B
Net debt
$20.41B
$48.49B
Debt / equity
0.7×
0.7×
Net debt / EBITDA (TTM)
2.3×
1.7×
Interest coverage (FY)
5.8×
4.7×
Current ratio (FY)
1.24
0.79
Dividends
trailing 12 monthsDividend yield
1.6%
2.2%
Dividends per share
$6.87
$9.06
Payout ratio (of TTM EPS)
29.3%
51.6%
Dividend per share, 5-year CAGR
9.6%
10.9%
Frequency
Quarterly
Quarterly
Ownership and activity
last 90 days · latest 13FTracked superinvestors holding (13F)
12
20
Insider open-market buys (Form 4)
$0
$0
Insider sales (Form 4)
$4.7M
$661K
Analyst upgrades
0
0
Analyst downgrades
0
0
Statements
income TTM to Sep 2026 · cash flow FY2025Revenue
$201.83B
$449.66B
EBITDA
$8.88B
$27.99B
Operating income
$7.46B
$23.92B
Net income
$5.14B
$15.88B
EPS (diluted)
$23.45
$17.56
Operating cash flow
$4.29B
$19.70B
Capital expenditure
−$1.12B
−$3.62B
Free cash flow
$3.17B
$16.07B
Dividends paid
$1.53B
$7.92B
Statements, prices, dividends and consensus estimates from Financial Modeling Prep; insider trades from Form 4 and holdings from 13F. Refreshed nightly. A comparison of filed numbers, not a recommendation to buy, sell or hold any security.